The authors concluded that NRF2 is a negative regulator of CXCL13 and a potential tumor suppressor in breast cancer, as also suggested by the presence of higher NRF2 levels in ER (−) breast cancer cells and the increased frequency of CXCL13/CXCR5 co-expression in ER (+) breast cancer cells with lower NRF2 contents. Here, ESR1 is linked to breast carcinoma.